Briefing
Residual ctDNA after treatment predicts early relapse in patients with early-stage NSCLC.
Landmark post-treatment ctDNA detection was associated with relapse (HR 20.7, 95% CI 7.7-55.5, P<0.0001). All 11 patients with landmark detection progressed, at a median of 121 days after detection, including all 8 who relapsed within 300 days of treatment. Among 27 patients who progressed, post-treatment ctDNA was detected in 17, with a median lead time of 203 days (up to 741 days).
- n: 88 patients, 363 plasma samples; landmark analysis in 62 patients (2 weeks to 4 months after initial treatment); 69 surgery, 19 chemoradiotherapy
- Assay: RaDaR personalized tumor-informed assay (up to 48 tumor-specific variants)